Skip to content
Home » Lung Cancer Genetic Testing: 6 Questions to Ask About Your Report

Lung Cancer Genetic Testing: 6 Questions to Ask About Your Report

Oncologist reviewing a lung cancer genetic testing report with a patient

A lung cancer genetic testing report identifies tumor features that may guide targeted therapy, immunotherapy, or clinical trial options. To understand what your results mean, confirm what was tested, which findings can guide care, and whether testing may need to be repeated.

Your report may contain unfamiliar gene symbols, percentages, and technical terms that are hard to interpret before an oncology appointment. The six questions below will help you review the findings, identify missing information, and discuss treatment decisions with your care team. They can also help you avoid assuming that a negative result means you have no remaining options.

What Your Lung Cancer Genetic Testing Report Actually Tells You

Lung cancer genetic testing, often called biomarker testing or molecular testing, examines the cancer for gene changes, proteins, and other measurable features. Some reports use next-generation sequencing (NGS), which checks many genes in one test. The findings can help your oncologist determine whether your cancer has a feature linked to a targeted medicine, immunotherapy, or clinical trial.

Most treatment-focused testing applies to non-small cell lung cancer (NSCLC), especially advanced lung adenocarcinoma. Your report should be interpreted alongside the cancer type, stage, biopsy findings, prior treatments, overall health, and treatment goals. A gene finding by itself does not automatically determine your treatment.

The report may also include programmed death-ligand 1 (PD-L1), a protein used when considering certain immunotherapies. PD-L1 is not a gene mutation, so it may appear in a separate part of the report. Ask your oncologist to explain how the genomic findings and PD-L1 result work together in your treatment plan.

Why “Genetic Testing” May Not Mean What You Think

Most lung cancer genetic testing examines acquired changes in the tumor, not genes you were born with. This is called somatic or tumor testing. These changes developed in cancer cells and usually are not present throughout your body or passed to your children.

Inherited testing, also called germline testing, looks for gene changes present in every cell. It is usually performed with a blood or saliva sample and answers a different question about inherited cancer risk. Seeing the word “genetic” on a tumor report does not mean your relatives have the same finding.

Ask whether your test was somatic, germline, or a test that could identify findings requiring follow-up germline testing. If the tumor result raises a possible inherited concern, your oncologist may recommend speaking with a genetic counselor. That professional can review your personal and family history and explain whether another test is appropriate.

Question 1: Which Biomarkers Were Tested, And Which Were Not?

Ask for the full list of genes, proteins, and alteration types covered by the test. A report can be described as “negative” even when it tested only a small number of biomarkers. Knowing the test’s scope helps you determine whether your report gives enough information to guide treatment.

Testing for advanced non-small cell lung cancer may include gene symbols such as EGFR, ALK, KRAS, ROS1, BRAF, MET, RET, NTRK, and HER2. The laboratory may look for several kinds of changes, including mutations, fusions, rearrangements, amplifications, and exon-skipping events. A test that checks a gene for one alteration type may miss a different type of clinically relevant change.

Ask whether the laboratory used a broad NGS panel, a small panel, or individual gene tests. You should also confirm whether PD-L1 was tested separately and whether the sample contained enough tumor material for reliable analysis. If tissue was insufficient, ask whether a blood-based liquid biopsy could provide added information.

Question 2: Were Any Actionable Mutations Found?

An actionable finding is a tumor feature that can help guide a treatment or clinical trial decision. Ask your oncologist to identify which results are actionable now, which may support a trial, and which do not currently change your care. Do not assume that every gene alteration listed on the report has a matching medicine.

Your report may place findings into categories based on the strength of the supporting evidence. Some findings are linked to an approved treatment for your type and stage of lung cancer. Others may be relevant only after a prior treatment, under specific clinical conditions, or through a research study.

Ask your oncologist to show you the exact alteration, not just the gene name. A result such as KRAS G12C or BRAF V600E is more specific than “KRAS positive” or “BRAF positive.” The precise alteration matters because different changes within the same gene do not always respond to the same treatment.

Question 3: What Do These Results Mean For My Treatment Options?

Your report may help determine whether targeted therapy, immunotherapy, chemotherapy, radiation, surgery, or a combination belongs in your plan. Ask which finding is driving the recommendation and what benefit the care team expects. You should also ask what factors could make a listed treatment unsuitable for you.

Targeted therapies are designed to interfere with proteins or signals that help certain cancers grow. A matched therapy may be considered when the tumor has the relevant target and the medicine is appropriate for the cancer’s type, stage, and treatment history. Resistance can still develop, so your oncologist should explain how the cancer’s response will be monitored.

PD-L1 results may help guide immunotherapy decisions, but the percentage should not be interpreted alone. A higher level may be associated with a greater chance of response in some treatment settings, yet people with lower levels can sometimes benefit. Ask how PD-L1, the tumor’s driver mutations, your health, and prior treatment affect the recommendation.

Question 4: Are There Clinical Trials That Match My Report?

Biomarker findings can help identify clinical trials studying treatments for a specific mutation, fusion, protein, or resistance mechanism. Ask your oncologist to search using the exact alteration written on your report. A trial search based only on “lung cancer” may return options that do not match your tumor.

Ask whether a trial is available locally or requires travel to another cancer center. Review the trial’s purpose, treatment phase, eligibility rules, required tests, visit schedule, possible costs, and whether you could receive a standard treatment outside the trial. These details can help you compare the study with your other options.

A trial discussion can still be useful when no approved targeted therapy matches the report. It may also become relevant later if the cancer changes or stops responding to treatment. Keep a digital or printed copy of the full laboratory report because trial teams often need the exact biomarker wording.

Question 5: Should My Family Be Concerned About Inherited Risk?

Most tumor biomarkers used to plan lung cancer treatment are acquired changes and do not mean that your relatives inherited the same alteration. Ask whether any finding on your report could represent a germline change. Your oncologist should distinguish a tumor-only result from an inherited cancer-risk result.

Your personal history and family cancer history may affect whether germline testing is considered. Tell your care team about close relatives who have had cancer, the cancer types involved, and whether anyone was diagnosed at an unusually young age. Do not ask relatives to order testing based solely on a tumor report without medical guidance.

If further evaluation is recommended, a genetic counselor can explain what the testing can and cannot establish. The counselor can also identify which relative should be tested first and how the result could affect medical care. This prevents family members from acting on a tumor finding that may have no inherited meaning.

Question 6: Will I Need Repeat Testing If My Cancer Changes?

Repeat biomarker testing may be considered if the cancer returns, grows during treatment, or stops responding to targeted therapy. Cancer cells can develop new changes that allow them to resist a medicine. A later test may identify a resistance mechanism or a different treatment opportunity.

Ask what change in your scans, symptoms, or treatment response would lead the team to order another test. Your oncologist may consider a new tissue biopsy, a liquid biopsy, or a review of earlier samples. The best option depends on where the cancer is located, how much tissue is available, and which alterations need to be assessed.

A liquid biopsy examines circulating tumor deoxyribonucleic acid (ctDNA) found in the blood. It can be useful when tumor tissue is difficult to obtain or when a faster blood draw is medically appropriate. A negative blood result does not always rule out a tumor alteration, so ask whether tissue testing is still needed.

How To Prepare For Your Next Oncology Appointment

Bring the complete laboratory report rather than a brief portal message stating that testing was positive or negative. Mark the specimen type, collection site, test method, genes examined, actionable findings, PD-L1 percentage, and any notes about insufficient material. Write down unfamiliar terms so the care team can explain them during the visit.

Ask your oncologist to connect every treatment recommendation to a specific report finding or clinical factor. Useful follow-up questions include how quickly a decision must be made, whether another test could change the plan, and what options remain if the recommended treatment does not work. Request a copy of the visit notes if you need help remembering the discussion.

You can bring a trusted caregiver to take notes and check that all six questions are addressed. Ask whether the report has been reviewed by a lung cancer specialist, molecular tumor board, or another qualified team. A second opinion may help when the findings are unusual, the sample was limited, or several treatment paths appear reasonable.

What To Do If Your Report Is Negative, Unclear, Or Incomplete

A negative report means the test did not detect the biomarkers it was designed and able to find. It does not prove that the tumor has no relevant alterations. The sample may have contained too few cancer cells, the panel may have covered too few genes, or the testing method may not have detected every alteration type.

Ask whether the report is truly negative or technically inconclusive. Terms such as “insufficient specimen,” “quantity not sufficient,” “low tumor content,” and “no circulating tumor DNA detected” describe limitations rather than a confirmed absence of biomarkers. Your oncologist can explain whether another tissue sample, liquid biopsy, or broader panel is justified.

No actionable mutation does not mean there are no treatment options. Your plan may still include immunotherapy, chemotherapy, surgery, radiation, supportive care, or a clinical trial, depending on your diagnosis. The useful question is not whether the report is good or bad, but which decisions it supports and what information is still missing.

Questions To Ask About A Lung Cancer Genetic Testing Report

  • Which biomarkers were tested?
  • Were actionable mutations found?
  • What treatments match my results?
  • Are matching trials available?
  • Could this finding be inherited?
  • Will I need repeat testing?

Turn Your Report Into A Clearer Treatment Discussion

Your lung cancer genetic testing report is a decision-making tool, not a result you’re expected to interpret alone. Confirm which biomarkers and alteration types were examined, then ask your oncologist to separate treatment-linked findings from results that do not currently affect care. Discuss clinical trials, inherited risk, sample limitations, and the conditions that could lead to repeat testing. Keep the full report because it may remain useful if you seek a second opinion or need to reconsider treatment later. The right questions can turn a dense laboratory document into a focused conversation about your available options.


References